Understanding Tumor and Immune Dynamics and Predicting Response to Various Perioperative Therapies in Patients With Muscle-invasive Bladder Cancer
Condition: Bladder Cancer
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT06341478
Sponsor: IRCCS San Raffaele
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: All
Inclusion Criteria:
- Inclusion in NureCombo (NCT04876313), SURE-01 (NCT05226117), and SURE-02 (NCT05535218) clinical trials or candidates to radical cystectomy as per routine clinical practice. 2. Histopathologically-confirmed urothelial carcinoma (UC). 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 4. Clinical stage T2-T4N0M0, muscle-invasive bladder cancer (MIBC)
Exclusion Criteria:
- Refusal to partecipate to the above studies
- Unavailability of baseline tumor and blood samples
View trial on ClinicalTrials.gov